Background: The emergence of resistant parasites to artemisinin poses a threat to malaria treatment. The study aimed to investigate K13 gene mutations in Plasmodium falciparum artesunate (AS)/sulfadoxine-pyrimethamine (SP) efficacy study in Sudan.
Methods: A total of 31 (14 failures and 17 adequate clinical and parasitological response [ACPR]) pretreatment dried blood samples from patients with uncomplicated P. falciparum malaria treated with AS/SP were examined. Nested polymerase chain reaction (PCR) and DNA sequencing of the K13 gene was performed.
Results: PCR products were obtained from 30 (96.8%) samples and sequencing was successful in 28 (90.3%). No mutation of the K13 gene was recorded in the treatment failure group. A single mutation (C>T; A621V) in one ACPR patient sample was detected.
Conclusion: There is no evidence of K13 mutation among AS/SP treatment failure patients. A single mutation of the K13 gene not linked to treatment failure has been detected.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/trstmh/trz027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and genetic diversity of polymorphisms in , and genes of in southern Côte d'Ivoire.
Malariaworld J
January 2025
Biosciences Training and Research Unit (UFR), Felix Houphouët-Boigny University, Abidjan, Côte d'Ivoire.
Background: has developed resistance to almost all the antimalarial drugs currently in use. This resistance has been and remains one of the greatest threats to the control and elimination of malaria. The use of molecular markers of resistance to monitor the emergence and spread of antimalarial drug-resistant parasite strains has proved highly effective.
View Article and Find Full Text PDFBackground: The treatment and control of malaria in Africa is challenged by drug resistance, including transporter, folate pathway, and PfK13 mutations that mediate resistance to aminoquinolines, antifolates, and artemisinins, respectively. Characterization of drug susceptibility informs optimal control strategies.
Methods: We characterized ex vivo susceptibilities to nine drugs of isolates collected from individuals presenting with uncomplicated falciparum malaria in eastern (2019-2024) and northern (2021-2024) Uganda using a growth inhibition assay and the dihydroartemisinin (DHA) ring survival assay (RSA).
sp. nov., and sp. nov., isolated from watermelon in Florida.
Int J Syst Evol Microbiol
December 2024
Department of Plant Pathology, University of Florida, Gainesville, FL, USA.
Three fluorescent bacterial strains, K1, K13 and K18, were obtained from watermelon () foliage symptomatic of bacterial leaf spot of cucurbits in Florida. The strains underwent phenotypic characterization, including LOPAT (levan production, oxidase activity, pectolytic activity on potato, arginine dihydrolase production and hypersensitive response (HR) on both tobacco and tomato) and pathogenicity testing on watermelon and squash seedlings. Whole-genome sequencing of the isolates was performed, and multi-locus sequence analysis (MLSA) utilizing housekeeping genes , , and placed the isolates into two distinct clades within the genus.
View Article and Find Full Text PDFTemporal genomics in Southern Zambia shows rising prevalence of Plasmodium falciparum mutations linked to delayed clearance after artemisinin-lumefantrine treatment.
Sci Rep
November 2024
Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, 02906, USA.
Article Synopsis
- * In a study in southern Zambia from 2013 to 2018, researchers genotyped 85.5% of Plasmodium falciparum samples, finding only one sample with a known resistance mutation and identifying five new mutations with low prevalence.
- * A significant 13% of isolates showed a mutation linked to delayed treatment clearance, which increased in prevalence over the study period, indicating that while common resistance mutations are rare, others may be evolving in response to selection pressures.
Background: Malaria in pregnancy is a major public health issue, particularly among vulnerable populations in malaria-endemic sub-Saharan African countries. To mitigate its risks, WHO recommends sulphadoxine-pyrimethamine (SP) for chemoprevention and artemisinin-based combination therapy (ACT) to treat uncomplicated malaria. These interventions have helped to alleviate the risk associated with malaria in pregnancy; however, in the context of the emergence of SP- and ACT-resistant , maintained efficacy is under threat.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!